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I. INTRODUCTION
Since the explosion of research in human genetics some 40 years ago, legal and ethical 
experts have found it increasingly difficult to balance societal interests in the advance-
ment of medical science with participants’ interests, concerns and expectations. The 
landmark decision in Moore v Regents of the University of California1—which ruled that 
tissue donors do not possess property rights in their excised tissue—as well as widespread 
fears that genetic information may be used for insurance or employment discrimination, 
have put ownership and confidentiality issues at the forefront of the debate.2 However, 
factors beyond the commonly anticipated risks must be taken into account when evalu-
ating current tissue research practices, especially as we have entered a new era of research 
using large biobanks. 
Recently, a lawsuit in which the Native American Havasupai tribe objected to 
research that had been done on their blood samples and to results that were stigmatis-
ing and disruptive to their self-understanding, has put the spotlight on a kind of harm 
that is frequently overlooked in current debates. The case under consideration, Havas-
* Kristof Van Assche and Serge Gutwirth, Vrije Universiteit Brussel (VUB), Belgium; Sigrid Sterckx, Ghent 
University and Vrije Universiteit Brussel (VUB), Belgium. All websites accessed June 2013.
1 Moore v Regents of the University of California, 793 P 2d 479, 489–92 (Cal 1990) (holding that a patient 
whose cell line was patented without his permission had no cause of conversion because he did not retain 
a sufficient property interest in his cells once they were extracted from his body).
2 Ted T Ashburn, Sharon K Wilson and Barry I Eisenstein, ‘Human Tissue Research in the Genomic Era of 
Medicine: Balancing Individual and Societal Interests’ (2000) 160(22) Archives of Internal Medicine 3377, 
3378–81. For an excellent overview of current biobank research issues, see Bernice Elger et al (eds), Ethi-
cal Issues in Governing Biobanks: Global Perspectives (Ashgate, 2008); Jane Kaye and Mark Stranger (eds), 
Principles and Practice in Biobank Governance (Ashgate, 2009). For some thought-provoking examples of 
biobank research that infringes on human dignity and autonomy, see Lori B Andrews and Dorothy Nelkin, 
Body Bazaar: The Market for Human Tissue in the Biotechnology Age (Crown, 2001); Donna L Dickenson, 
Property in the Body: Feminist Perspectives (Cambridge University Press, 2007).
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upai Tribe v Arizona Board of Regents, reveals that biobank research can lead to so-called 
‘dignitary harms’, which involve infringement on the autonomy, privacy or moral integ-
rity of the research participants. In this article, we provide several illustrations of such 
harms and argue that they should be taken seriously and that both the regulatory and the 
legal framework should be revised to more adequately protect the interests of biobank 
research participants. 
We begin with a discussion of the details of the Havasupai case, relying heavily on 
the so-called Hart Report.3 Subsequently we provide some examples of ‘non-obvious’ 
tangible harms which may occur in the context of biobank research. This is followed by 
an investigation into the meaning, relevance and possible manifestations of (intangible) 
‘dignitary harm’. The next part of the paper considers the Code of Federal Regulations 
and identifies major flaws which are exposed by the Havasupai case. We proceed to show 
that biobank research participants seeking redress under present tort doctrine will be left 
without a remedy, because courts have not recognised a duty of special care outside the 
therapeutic setting and have not considered dignitary harms to be compensable injuries. 
In the final part of the paper we suggest two ways in which current tort doctrine could be 
modified to better protect the dignity of biobank research participants—one involving 
an expansion of existing remedies and the other concerning the development of a dis-
tinct dignitary tort. By way of conclusion, we summarise some of the main implications 
of the Havasupai case for present-day biobank research practices and the regulatory and 
legal frameworks that govern them.
II. BACKGROUND TO THE HAVASUPAI CASE
The Havasupai are a Native American tribe, inhabiting a vast (760 km²) reservation at 
the bottom of the Grand Canyon, Arizona. Today, the tribe counts about 650 members, 
nearly all living in or around the remote village of Supai.4 Since the 1960s, the Havas-
upai have experienced a rapid increase in the incidence of type 2 diabetes.5 Dozens of 
3 As will be explained in more detail below, the Hart Report set out the investigative findings of attorneys 
Stephen Hart and Keith Sobraske, who were appointed by the Arizona Board of Regents to ‘investigate the 
circumstances surrounding the collection of blood samples and other data from members of the Tribe and 
any and all subsequent uses of the data and the samples or their derivatives’. See Stephen Hart and Keith 
Sobraske, Investigative Report Concerning the Medical Genetics Project at Havasupai (23 December 2003), 
Investigative Assignment and Scope of Investigation, 4 http://cnhp.montana.edu/conference/HartReport.
pdf.
4 Official website of the Havasupai Tribe, www.havasupai-nsn.gov/index.html.
5 The Havasupai tribe has the fourth highest prevalence of diabetes of any population in the world (46%), 
three times higher than the statistical average for Native Americans (16%) and more than six times higher 
than the statistical average for non-Hispanic whites (7%). It is one of the leading causes of death in 
Havasupai adults. See National Diabetes Information Clearinghouse, National Diabetes Statistics (NDIC 
2011), http://diabetes.niddk.nih.gov/dm/pubs/statistics/DM_Statistics.pdf.
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Havasupai diabetics have had their lower limbs amputated or have been forced to leave 
the canyon for dialysis.6
Because diabetes had such a devastating effect on their community, in July 1989 
tribal leaders approached John Martin, an anthropology professor from Arizona State 
University (ASU), to look into its causes. After spending more than a year in Supai in 
the early 1960s and writing his PhD on the Havasupai, Martin had developed a strong 
relationship with them. He had written extensively on their customs and traditions and 
made a good academic career out of it.7 Since the Havasupai, like other Native Ameri-
cans, were deeply suspicious of exploitation by outsiders and considered their bodies to 
be sacred, the special trust placed in Martin proved crucial to overcoming the reluctance 
of tribe members to participate in the project.8
Martin suspected that the diabetes epidemic was related to genetics and diet, and 
he contacted genetics professor Therese Ann Markow and nutrition professor Linda 
Vaughan, both from ASU. Markow was not an expert on diabetes. However, she was 
ASU’s only human geneticist at the time and a rising star, known for her success in win-
ning research grants. Whilst approached to study diabetes, Markow was interested in the 
prospect of studying the high incidence of schizophrenia that the Havasupai allegedly 
also suffered from. She would later claim that Martin had lured her into the diabetes 
project by mentioning that the incidence of schizophrenia was seven times higher than 
normal and that he could provide her with genealogical and demographic reports dat-
ing from 1896.9 During the preparatory meetings, Markow expressed a desire to include 
schizophrenia, but was told by Martin that the Havasupai would be unlikely to be 
interested, at least at this point. However, Markow almost immediately submitted an 
application to the National Alliance for Research on Schizophrenia and Depression for a 
grant to study schizophrenia among the Havasupai.10
Markow, Martin and Vaughan designed a diabetes project that they proposed at a 
meeting of the Havasupai Tribal Council in March 1990: an educational pilot program 
(for which funding had already been obtained); a summer school at ASU for about 10 
Havasupai women, educating them about diabetes and the role of good nutrition in 
prevention; collection and analysis of blood samples to identify individuals susceptible 
to the disease; and tests to determine whether there was a clear genetic cause.11
6 Amy Harmon, ‘Indian Tribe Wins Fight to Limit Research of Its DNA’, New York Times (22 April 2010), A1.
7 Hart and Sobraske (n 3) Witness Interview Summaries, 153–4.
8 According to his assistant Daniel Benyshek, John Martin was the ‘only reason why the project worked at all’. 
Because he had developed a lot of trust, ‘over the course of many informal talks, community and Council 
meetings, Martin was able to engender unusually high support for the project’. Ibid, 26.
9 Ibid, 8, 132, 168. See also Paul Rubin, ‘Indian Givers’, Phoenix New Times (27 May 2004), www.phoenixnew 
times.com/2004–05–27/news/indian-givers.
10 She had understood that, as a small, genetically isolated population, the Havasupai would offer her a 
unique chance to discover rare gene variants.
11 Hart and Sobraske (n 3) Witness Interview Summaries, 27–28, 158–9, 218–19. Recently, a link had been 
reported between a genetic variant and the high rate of type 2 diabetes among the Pima, a Native American 
tribe from Arizona. See Robert C Williams et al, ‘HLA-A2 and Type 2 (Insulin Independent) Diabetes 
Mellitus in Pima Indians: An Association of Allele Frequency with Age’ (1981) 21(5) Diabetologia 460.
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In May 1990, after careful deliberation, the Havasupai Tribal Chair wrote to Mar-
tin to confirm that the diabetes project could proceed. However, Markow had already 
obtained funding for the schizophrenia research, without informing the Havasupai.12
In June 1990, before funding was obtained for the diabetes study, blood draws 
started on more than 100 Havasupai. Except for Markow and Kevin Zuerlein, the young 
psychiatrist she had appointed to coordinate the draws, all parties concerned were con-
vinced that they were participating only in diabetes research. The first series of blood 
draws was in fact paid for with money from the schizophrenia grant.13 Moreover, Zuer-
lein was instructed to surreptitiously scan the medical files in the tribal clinic for records 
of psychiatric distress.14 Markow insisted on securing a general informed consent from 
Havasupai blood donors. Surprisingly, Martin—who meanwhile had learned that 
Markow had obtained funding to study schizophrenia and claims to have told her again 
that the Havasupai simply would not be interested—was agreeable to this.15
The consent form was kept deliberately vague, stating that the purpose of the 
project was to ‘study the causes of behavioral/medical disorders’.16 However, in all deal-
ings with the tribe, only diabetes research was mentioned and individual donors were 
convinced that research would be limited to this topic.17 The ASU Institutional Review 
Board approved Markow’s schizophrenia study in January 1991 and her diabetes study 
in March 1991, months after work on these projects had begun.18 
In July 1991, a second series of blood draws was initiated, which proceeded inter-
mittently until the summer of 1994 and involved an additional 130 members of the 
Havasupai.19 According to Daniel Benyshek, an assistant of Martin who coordinated 
these blood draws, no written informed consent was sought.20 He would later claim 
to have been advised by Charlotte Beauty, the Havasupai nurse performing the blood 
draws, that the written consent documents would confuse the tribal members and that 
12 Hart and Sobraske (n 3) Investigative Findings, 23–24.
13 Ibid, 45.
14 Hart and Sobraske (n 3) Witness Interview Summaries, 239.
15 Ibid, 155.
16 Hart and Sobraske (n 3) Investigative Findings, 58.
17 Ibid, 50–52. 
18 Ibid, 24.
19 According to Benyshek’s records, more than a third of tribe members donated blood specimens. The Hart 
Report could only ascertain 208 Havasupai blood donors. See Hart and Sobraske (n 3) Witness Interview 
Summaries, 25, 30, 175; Investigative Findings, 2.
20 Hart and Sobraske (n 3) Witness Interview Summaries, 31, 35. When confronted with Benyshek’s statement, 
Markow reacted in a curious way. She indicated that he had obtained written consent forms from every 
participant but that she had lost the file containing them when she moved from ASU to the University 
of Arizona (UA) in the mid-1990s. However, in the same interview she said that she was surprised when 
she learned that Benyshek had not obtained signed consents and that she felt that he must have been 
aware of the need to secure them. Ibid, 139. None of the researchers working on the genetics project could 
remember ever having seen signed consent documents pertaining to the second series of blood draws. Ibid, 
19, 63, 76, 179, 202–3.
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providing purely oral information would be more convincing. The information Beny-
shek provided to the tribal members focused only on diabetes and emphasised that, with 
a view to better treatment and prevention, blood samples would be analysed in order to 
understand how diabetes passed from one generation to another.
Soon after it started, the diabetes-genetic study was put on the backburner. Analysis 
of the blood samples and the medical files of the Indian Health Service clinic in Supai 
had shown that the Havasupai indeed had an extremely high incidence of type 2 diabe-
tes, affecting 38 per cent of men and 55 per cent of women over the age of 35. However, 
the ASU researchers concluded that the incidence of diabetes had risen too quickly to be 
related to genetics.21 With hopes of finding an answer seemingly lost, the genetic diabe-
tes research was essentially abandoned without the tribe members being informed about 
the conclusions that were reached. Martin, Vaughan and Benyshek instead concentrated 
on nutritional factors, suggesting that the high-fat, sugar-laden diet of the Havasupai 
contributed to childhood obesity and the onset of type 2 diabetes.22
After the research on genetic markers for diabetes ended in 1991, Markow and her 
collaborators continued to conduct research on samples from and data regarding tribal 
members. Over the following years, a good deal of research was conducted in Markow’s 
main field of interest, schizophrenia. Beginning in September 1991, her doctoral assist-
ant, Christopher Armstrong, analysed the Havasupai blood samples, hoping to find a 
genetic variation that could be associated with the development of schizophrenia. How-
ever, while Armstrong claimed to have found a genetic variation that could be relevant, 
he was unable to link this finding with the incidence of schizophrenia among the Havas-
upai.23 Moreover, the medical files that Zuerlein had reviewed in the Havasupai clinic 
did not reveal unusual levels of psychiatric distress.
Apart from the schizophrenia study, Havasupai data were also used to conduct 
research regarding two other topics that the tribe members had not validly consented 
to. In 1993, a paper was published by Markow and Martin reporting that indicators 
of inbreeding among the Havasupai were among the highest reported for any group.24 
The inbreeding study involved 36 Havasupai handprints that were collected by Benyshek 
21 Kevin Zuerlein, John F Martin, Linda Vaughan and Therese A Markow, ‘NIDDM: Basic Research Plus 
Education’ (1991) 338(8777) Lancet 1271.
22 Linda A Vaughan, Daniel C Benyshek and John F Martin, ‘Food Acquisition Habits, Nutrient Intakes, and 
Anthropometric Data of Havasupai Adults’ (1997) 97(11) Journal of the American Dietetic Association 
1275; Daniel C Benyshek, John F Martin and Carol S Johnston, ‘A Reconsideration of the Origins of the 
Type 2 Diabetes Epidemic among Native Americans and the Implications for Intervention Policy’ (2001) 
20(1) Medical Anthropology 25; Daniel C Benyshek, ‘The Nutritional History of the Havasupai Indians of 
Northern Arizona: Dietary Change and Inadequacy in the Reservation Era and Possible Implications for 
Current Health’ (2003) 26(1–2) Nutritional Anthropology 1.
23 Hart and Sobraske (n 3) Witness Interview Summaries, 11. Sixty-nine tribal blood samples were used in 
the context of Armstrong’s PhD research on the general etiology of schizophrenia. Ibid, 140, 242.
24 Therese A Markow and John F Martin, ‘Inbreeding and Developmental Stability in a Small Human 
Population’ (1993) 20(4) Annals of Human Biology 389.
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during the second series of blood draws. As with the blood draws, no informed consent 
was obtained. Rather unconvincingly, Martin later suggested that inbreeding research 
could yield important insights into developmental instability patterns that might play a 
role in diabetes.25
Until 1993–4, the genetic research on the Havasupai focused exclusively on 
behavioural and medical disorders. Although, diabetes aside, the ASU researchers’ com-
munications with the Havasupai tribe members were too misleading for their consent to 
be truly informed, this kind of research still fell under the scope of the project described 
in the written consent document signed by the participants in the first series of blood 
draws. However, that was no longer the case when, a few years later, the focus changed to 
population migration. After Markow had moved from ASU to the University of Arizona 
(UA) and had taken the Havasupai blood samples with her, she provided samples to 
UA researchers with a keen interest in ancient population migration theory.26 The sam-
ples were analysed to trace the origins of the tribe by comparing DNA of its members 
with that of other groups. By showing that it was probable that the Havasupai’s ances-
tors had reached America by crossing the Bering Straits, conclusions were reached that 
were inconsistent with the beliefs of most Havasupai tribal members.27 For this use of 
the samples, no permission was sought from the tribe or from any Institutional Review 
Board.
Markow also sent some of the blood samples to researchers from other universities, 
despite the fact that the written consent form had stipulated that no information on the 
Havasupai would leave ASU. When later confronted about this, she insisted that, since 
those samples were coded and individual donors could not be identified, no information 
had left ASU.28
Apart from Armstrong, none of the researchers involved seemed to have any moral 
qualms about the ways the Havasupai samples and data were used and whether these 
uses were authorised. On numerous occasions in 1996 and 1997, Armstrong commu-
25 Hart and Sobraske (n 3) Witness Interview Summaries, 152.
26 Ibid, 144–5.
27 In 1997, UA researchers published a paper concerning 10 Havasupai samples; this paper supported the 
hypothesis of a single wave of migration into the New World instead of the three-wave migration model 
that was dominant at the time. See Tatiana M Karafet et al, ‘Y Chromosome Markers and Trans-Bering 
Strait Dispersals’ (1997) 102(3) American Journal of Physical Anthropology 301. In 1999, another paper was 
published concerning the same samples; this paper supported the possibility of two waves of migration. 
See Tatiana M Karafet et al, ‘Ancestral Asian Source(s) of New World Y-Chromosome Founder Haplotypes’ 
(1999) 64(3) American Journal of Human Genetics 817. Finally, in 2004, the same research team published 
a paper in which no use was made of Havasupai samples; this paper suggested one wave of migration 
occurring no more than 17,000 years ago. See Stephen L Zegura, Tatiana M Karafet, Lev A Zhivotovsky and 
Michael M Hammer, ‘High-Resolution SNPs and Microsatellite Haplotypes Point to a Single, Recent Entry 
of Native American Y Chromosomes into the Americas’ (2004) 21(1) Molecular Biology and Evolution 
164. However, despite a vast body of research, considerable disagreement remains within the research 
community as to the number and timing of the early migration waves into the Americas.
28 Hart and Sobraske (n 3) Witness Interview Summaries, 138. The researchers concerned all confirmed that 
the samples they received did have a code system with identification numbers and that they had no access 
to any names or pedigree information. Ibid, 67, 90, 126, 194.
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nicated to Markow that she was guilty of research misconduct. He also notified ASU 
officials.29 However, although Armstrong was rebuked by ASU’s lawyer for having made 
‘serious and defamatory allegations’ against Markow, no further action was taken by 
ASU until March 2003, when, invited by Martin, a tribal leader attended a PhD defence 
in ASU concerning diabetes-related research on Havasupai blood samples but also men-
tioning the population migration research.30 Shocked by this, the Havasupai issued a 
‘banishment order’ to forbid ASU employees from setting foot on their reservation. 
ASU’s President was informed about the Havasupai complaints and was asked to make 
reparations, but did not react until it came to his attention that the tribe intended to hold 
a press conference to publicise the matter.31 ASU then suggested to the tribe that a jointly 
selected independent investigator be appointed to investigate what had happened. The 
tribe accepted and signed a Joint Confidentiality and Cooperative Investigation Agree-
ment with ASU. However, because ASU unilaterally selected Phoenix attorneys Stephen 
Hart and Keith Sobraske to perform the investigation, the Havasupai declined to lift 
their banishment order. As a result, Hart and Sobraske had to rely exclusively on inter-
views with 34 academics and officials from ASU and elsewhere.32 
In December 2003, Hart and Sobraske issued their final report, finding no firm evi-
dence of research misconduct but listing important issues concerning the administration 
of the project and especially the scope of the consent.33 The report uncovered numer-
ous studies and projects carried out at various universities and laboratories throughout 
the United States, resulting in at least 23 scholarly articles and dissertations involving 
Havasupai blood samples. Only eight of these publications dealt with diabetes, whereas 
the others focused on schizophrenia, inbreeding and population migration.34 The Hart 
Report also revealed that the principal researchers held contradictory views on the 
nature of their original project. According to Martin and Vaughan, the project was only 
about diabetes, notwithstanding the fact that the informed consent form referred more 
generally to ‘behavioral/medical disorders’. Markow, on the other hand, maintained that 
the project included the study of any medical or behavioural disorder. She considered 
that pressing medical problems that Martin had told her about, such as schizophrenia, 
fell under the umbrella of the project and that the informed consent form was formu-
lated to encompass all diseases affecting the Havasupai tribe.35
29 Ibid, 15–16, Investigative Findings, 28–29.
30 In response to a request by Martin, the chapter mentioning the Havasupai was removed from the 
dissertation and an article based on this chapter was withdrawn prior to publication. See Hart and Sobraske 
(n 3) Witness Interview Summaries, 85, 102.
31 Havasupai Tribe v Arizona Board of Regents, 204 P 3d 1063, 1067 (Ariz Ct App 2008).
32 Hart and Sobraske (n 3) Investigative Findings, 4, 49.
33 Ibid, 2–3.
34 Ibid, 70–145. See also Larry Hendricks, ‘Havasupai Tribe Files $50M Suit against ASU’, Arizona Daily Sun 
(16 April 2004), www.ipcb.org/issues/human_genetics/htmls/havasupai.html.
35 Hart and Sobraske (n 3) Investigative Findings, 58–59, 83, 117–18, Witness Interview Summaries, 132, 
136–7, 155.
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The Havasupai were very upset to learn how their blood samples had been handled 
by ASU researchers—particularly how they had been used for unauthorised studies with 
potentially extremely undesirable effects on their community.36 The Havasupai objected 
to the schizophrenia research, claiming that it could stigmatise their tribe. They were 
offended by the inbreeding paper, because apart from stigmatisation it caused major con-
cern based on their cultural belief that inbreeding brings harm to one’s family. Further, 
they were shocked by the population migration study, because its conclusions contra-
dicted their belief that they had originated in the Havasu canyon and were assigned to 
be its guardian.37
The Havasupai filed several notice-of-claim letters. They contended that the 
improper use of their blood samples had invaded both their personal privacy and the 
‘cultural and religious privacy’ of the tribe, and had caused them severe harm, extreme 
distress and emotional trauma. In addition, they claimed that this misconduct had 
resulted in a growing mistrust of medical care, because many tribe members now feared 
going to the health clinic, seeking medical attention, and providing blood samples for 
medical diagnosis or treatment.38
When no settlement was reached, two separate lawsuits were filed in February and 
March 2004, one by 52 tribe members who had participated in the blood draws and 
the other by the Havasupai tribe, on its own behalf and in parens patriae. These law-
suits were directed at the Arizona Board of Regents (ABOR), the governing body of 
Arizona’s public university system supervising ASU and UA, and at Markow, Martin and 
Benyshek. The plaintiffs requested a halt to all use and transfer of the blood samples, 
genealogy information and handprints, the prevention of any further publication or 
sharing of that information, and the return of all remaining samples. Claims were filed 
alleging breach of fiduciary duty, lack of informed consent, fraud and misrepresentation, 
fraudulent concealment, intentional infliction of emotional distress, negligent infliction 
of emotional distress, conversion, violation of civil rights, negligence, negligence per se, 
and gross negligence, for a total of $60 million in damages.39 A long procedural battle 
ensued, ending before the Court of Appeals of the State of Arizona in November 2008, 
when it became clear that the substantive case would have to be heard in court unless a 
settlement was reached.40 In April 2010, after more than six years of legal battle and $1.7 
million spent by ABOR on legal costs, a settlement was indeed reached. ABOR agreed to 
pay the plaintiffs $700,000 and to return all remaining blood samples as well as docu-
36 Havasupai blood donors were appalled to learn that many of their blood lines had died during a freezer 
malfunction due to negligent maintenance. See Hart and Sobraske (n 3) Witness Interview Summaries, 
11–12, 145–6.
37 Harmon (n 6).
38 Tilousi v Arizona Board of Regents, 2007 WL 4934760 (Ariz App Div 1), No 1 CA-CV07-0801, Plaintiffs-
appellants’ opening brief, 7–8, 21, appendix 1.
39 Ibid, appendix 1–4; Havasupai Tribe (n 31) 1068–70.
40 Havasupai Tribe (n 31) 1081.
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ments containing research derived from the blood samples. In addition, ABOR initiated 
a five-year collaborative project in the areas of education, clinical care and tourism.41
The importance of the Havasupai case cannot easily be overstated. By way of obiter 
dictum from the Arizona Court of Appeals, the fact that ‘dignitary interests’ must be 
taken into account when evaluating biobank research was for the first time explicitly 
acknowledged in this case. Indeed, research participants may have interests that go 
beyond the safety and confidentiality considerations that most often dominate the ethi-
cal and regulatory debates. The next section discusses a few examples of ‘non-obvious’ 
(and hence easily overlooked) tangible harm. This is followed by an overview of (intan-
gible) ‘dignitary’ harms that may occur. We provide illustrations from the Havasupai and 
other cases and explain why such harms need to be taken seriously.
III. ‘NON-OBVIOUS’ TANGIBLE HARMS
Discussions of the ethical and legal issues in biobank research frequently only consider 
potential harms of a physical or informational nature to be relevant. The risk of physi-
cal harm is usually regarded as minimal. As regards the risk of informational harm, it 
is indeed true that inappropriately disclosed personal health information that derives 
from biobank samples may expose sample providers to insurance or employment dis-
crimination and hence to economic harm.42 However, the actual extent of this kind of 
discrimination remains a matter of speculation, especially after the Genetic Informa-
41 Communication by the Arizona Board of Regents, https://azregents.asu.edu/palac/newsreleases/Hava 
supai-ABOR-Lawsuit.htm.
42 In Norman-Bloodsaw v Lawrence Berkeley Lab, 135 F 3d 1260, 1267, 1275 (9th Cir 1998), seven (former) 
administrative and clerical employees filed suit against their employer for violating their right to privacy 
because employment was conditioned on mandatory preplacement examinations involving non-con-
sented-to genetic testing for syphilis, sickle cell traits and pregnancy. The Court of Appeals stated that ‘it 
goes without saying that the most basic violation possible involves the performance of unauthorized tests’ 
and ruled that the District Court erred in dismissing the plaintiffs’ privacy claims. In Equal Employment 
Opportunity Commission v Burlington Northern and Santa Fe Railway Company, Civ No 01-4013 (ND Iowa 
2001), the Equal Employment Opportunity Commission filed a petition alleging a violation of the Ameri-
cans with Disabilities Act in relation to the employer’s request that employees who developed carpal tunnel 
syndrome undergo physical examinations involving non-consented-to genetic testing to identify a genetic 
defect allegedly predisposing individuals to this type of condition. Before the case was heard, the defen-
dant announced that it would cease its genetic testing program and a settlement agreement was reached. 
See Press Release, Equal Employment Opportunity Commission, ‘EEOC Settles ADA Suit against BSNF 
for Genetic Basis’ (18 April 2001), www.eeoc.gov/eeoc/newsroom/release/4–18–01.cfm. For further back-
ground, see Patricia A Roche, ‘The Genetic Revolution at Work: Legislative Efforts to Protect Employees’ 
(2002) 28(2–3) American Journal of Law and Medicine 271; Ashley M Ellis, ‘Genetic Justice: Discrimination 
by Employers and Insurance Companies Based on Predictive Genetic Information’ (2003) 34(4) Texas Tech 
Law Review 1071; Kimberly G Fulda and Kristine Lykens, ‘Ethical Issues in Predictive Genetic Testing: A 
Public Health Perspective’ (2006) 32(3) Journal of Medical Ethics 143; Louise M Slaughter, ‘Genetic Testing 
and Discrimination: How Private Is Your Information?’ (2006) 17(1) Stanford Law & Policy Review 67.
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tion Non-Discrimination Act came into effect.43 Moreover, an exclusive focus on these 
types of harm may push other risks out of sight. For instance, while the possibility of 
physical harm arising from biobank research is usually rejected out of hand, it is quite 
conceivable that research participants could suffer indirect physical harm when they are 
exploited, and consequently lose their trust in the medical profession. The Havasupai 
case is an appropriate example, because, as was emphasised during the proceedings, the 
improper use of their samples left many blood donors afraid of going to the health clinic, 
seeking medical attention, and providing further blood samples for medical diagnosis or 
treatment.44
Yet other tangible harms may arise—even harms affecting a whole community—
from certain forms of research. In the case of Native American tribes that enjoy extensive 
sovereignty, being labelled with a stigmatising condition could result in downgrading 
the community’s bond rating, making it more difficult to obtain financing.45
Another concern, which was explicitly voiced by one of the Havasupai leaders, is that 
legal entitlements might be threatened when, as was the case with the population migra-
tion study, genetic tests reveal that the tribe did not originate in its current location.46
IV. DIGNITARY HARM
The Concept of Dignitary Harm
Apart from the abovementioned ‘non-obvious’ but potentially formidable tangible 
harms, biobank research can also lead to severe intangible harms. Our focus here is on 
43 See Allen Buchanan, ‘An Ethical Framework for Biological Samples Policy’ in National Bioethics Advisory 
Commission (ed), Research Involving Human Biological Materials: Ethical Issues and Policy Guidance, vol 2 
(NBAC, 2000) B1, B6; Henry T Greely, ‘Genotype Discrimination: The Complex Case for Some Legislative 
Protection’ (2001) 149(5) University of Pennsylvania Law Review 1483, 1490; Jeffrey S Morrow, ‘Insuring 
Fairness: The Popular Creation of Genetic Antidiscrimination’ (2009) 98 Georgetown Law Journal 215, 
225. The Genetic Information Non-Discrimination Act (Pub L 110-233, 122 Stat 881), prohibiting health 
insurance and employment discrimination on the basis of genetic information, was signed into law by 
President Bush on 21 May 2008 and came into effect on 21 May 2009 (for health insurance companies) and 
21 November 2009 (for employers): www.gpo.gov/fdsys/pkg/PLAW–110publ233/pdf/PLAW–110publ233.
pdf.
44 Havasupai Tribe (n 31) 1069.
45 In 1979, findings of a research study examining the alcohol intake of the Inupiaq residents of Barrow were 
misinterpreted by reporters as showing that they were irresponsible alcoholics. As a result, the Inupiaq 
community’s bond rating was reduced and funding for key projects denied. See EF Foulks, ‘Misalliances 
in the Barrow Alcohol Study’ (1989) 2(3) American Indian and Native Alaska Mental Health Research 
18; Carol E Kaufman and Saumya Ramarao, ‘Community Confidentiality, Consent, and the Individual 
Research Process: Implications for Demographic Research’ (2005) 24(2) Population Research and Policy 
Review 149, 155.
46 Harmon (n 6); JL McGregor, ‘Population Genomics and Research Ethics with Socially Identifiable Groups’ 
(2007) 35(3) Journal of Law, Medicine and Ethics 356, 363.
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so-called ‘dignitary harms’. In the context of the topic of this paper, these are at issue 
when research participants are not respected as persons but are denied respect for their 
humanity and used merely for the ends of others. Irrespective of other, palpable negative 
effects that may result from biobank research, these harms arise from the fact that par-
ticipants were not treated with the dignity and respect they deserve.47 More specifically, 
dignitary harms involve infringement on the autonomy, privacy and moral integrity of 
research participants. As persons, they have an inalienable right to decide for themselves 
and to act upon their decisions without outside interference; they are entitled to a per-
sonal sphere free from public attention and intrusion; and they deserve respect for who 
they are and for the values, preferences and commitments they subscribe to.
Why Should We Care about Dignitary Harms? 
As has been forcefully argued by bioethicist Julian Savulescu with regard to the use of 
leftover body material for research purposes:
Each mature person should be the author of his or her own life. Each person has values, 
plans, aspirations, and feelings about how that life should go. People have values which may 
collide with research goals … To ask a person’s permission to do something to that person is 
to involve her actively and to give her the opportunity to make the project a part of her plans. 
When we involve people in our projects without their consent we use them as a means to our 
own ends.48
Even when research participants have consented to their samples being used in certain 
specified ways, a situation may arise where these samples are used for a purpose that was 
only ambiguously defined in the original consent form, and donors who did not realise 
the full implications of their consent should still be allowed to stop uses of their samples 
to which they object. This right can be illustrated with an example given by Søren Holm 
regarding the rights of donors of stem cell lines: 
Let us imagine that a stem cell line derived from an embryo I have donated can develop into 
a kind of tissue called bronchial epithelia, and let us assume further that I have consented to 
‘any research or medical use.’ The tissue has no specific therapeutic value but it is very useful 
for toxicological testing of inhaled substances. It therefore becomes the de facto standard in 
pulmonary toxicology screening and is produced and sold in large quantities. I discover that 
although the pharmaceutical industry is a major user of this tissue, the largest users are Phil-
47 See Dan B Dobbs, Law of Remedies: Damages, Equity, Restitution (West, 2nd edn 1996) 623 (‘[D]ignitary 
harms may cause economic harm as well as affront to personality. If so, economic damages may be recov-
ered. However, in a great many … cases, the only harm is the affront to the plaintiff ’s dignity as a human 
being, the damage to his self-image, and the resulting mental distress’).
48 Julian Savulescu, ‘For and Against: No Consent Should Be Needed for Using Leftover Body Material for Sci-
entific Purposes—Against’ (2000) 325(7365) British Medical Journal 648, 649. A similar opinion is voiced 
in Rosamond Rhodes, ‘Rethinking Research Ethics’ (2005) 5(1) American Journal of Bioethics 7, 16–17.
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lip Morris and British American Tobacco. Being strongly opposed to the immoral marketing 
tactics of the tobacco industry, I feel aggrieved and want to stop their use of ‘my’ cell line. Are 
there any good reasons why I should not be allowed to do this?49
Moreover, having one’s body material used for purposes one is morally opposed to may 
make one feel morally complicit. ‘Moral complicity’ refers to the idea that one can do 
wrong by being associated in some way with wrongdoing by others, for example by caus-
ally contributing to others’ wrongdoing in a certain way or by increasing the likelihood 
of the wrongdoing occurring even without causing it in any way.50 Allowing people to 
avoid moral complicity is an additional reason for avoiding dignitary harms in research.
The fact that dignitary harm usually cannot be proven (unlike, for example, physical 
harm) is not a convincing reason to disregard it. According to the majority opinion of 
the Arizona Court of Appeals in the Havasupai case: 
The allegations [made by the Havasupai] present information from which injury might be 
inferred, which injury is necessarily personal and subjective and difficult to quantify, and 
which injury need not be established with regard to dignitary torts because it is presumed.51
Especially in the case of so-called ‘population isolates’, the prospect of gaining novel 
insights into complex diseases may sometimes prove too hard to resist for researchers 
to give proper consideration to the interests and concerns of the target group. Conse-
quently, research participants risk being treated merely as means for the pursuit of other 
people’s ends and being used in research without benefiting from it.52
Potential Manifestations of Dignitary Harm
Sometimes dignitary harms manifest themselves as psychosocial harms, especially when 
information is released that is stigmatising or upsetting to the participants. In such cases, 
research participants run the risk of being regarded in a more negative way or even 
of suffering a loss of self-esteem, which may damage their relationships with others. 
Moreover, if research suggests a linkage between one ethnic group and the prevalence of 
49 Søren Holm, ‘Who Should Control the Use of Human Embryonic Stem Cell Lines? A Defence of the 
Donors’ Ability to Control’ (2006) 3(1–2) Journal of Bioethical Inquiry 55, 59.
50 For interesting readings on moral complicity, see Christopher Kutz, Complicity: Ethics and Law for a 
Collective Age (Cambridge University Press, 2000); Ronald M Green, ‘Benefiting from “Evil”: An Incipient 
Moral Problem in Human Stem Cell Research’ (2002) 16(6) Bioethics 544; Helen Watt (ed), Cooperation, 
Complicity & Conscience: Problems in Healthcare, Science, Law and Public Policy (Linacre, 2006); John 
Gardner, ‘Complicity and Causality’ (2007) 1(2) Criminal Law and Philosophy 127.
51 As summarised in Judge Thomson’s dissenting opinion: see Havasupai Tribe (n 31) 1081.
52 Ernest Wallwork, ‘Ethical Analysis of Research Partnerships with Communities’ (2008) 18(1) Kennedy 
Institute of Ethics Journal 57, 67. Even if the research in question concerns a condition that members of the 
studied group suffer from, there is no guarantee that the research will yield any benefit to them, because any 
product or intervention that is developed on the basis of the research may be inaccessible or unaffordable 
or even ineffective for them.
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a psychiatric condition, or a socially unacceptable practice like inbreeding, individuals 
may suffer psychosocial harms simply by being members of that group.53 In the Havas-
upai case, for instance, information gleaned from donated biological samples reinforced 
the racial stereotype that Native Americans are unusually susceptible to certain types of 
disease.
Perhaps even more detrimental than external stereotyping is the risk of cultural 
harm, which may eventually lead to community disruption.54 Biobank research that 
undermines cultural and spiritual beliefs may indeed be devastating to the self-under-
standing of the community. In the Havasupai case, the self-representation of the group 
was severely disturbed in at least three ways. The schizophrenia study was based on the 
presumption that the alleged high incidence of schizophrenia may have originated with 
a tribal shaman living in the late nineteenth century, clearly suggesting that one of the 
most important historical spiritual leaders of the Havasupai was insane.55 The inbreed-
ing study, for its part, touched on a major taboo, because according to the cultural beliefs 
of the tribe this kind of behaviour brings misfortune to one’s family.56 But what really 
shook the community to its foundations was that the tribe’s origin myth was discredited 
when the population migration study showed that the tribe had not originated in the 
Grand Canyon but had entered North America from Siberia. By upsetting the Havas-
upai’s historical narrative, their sense of themselves and of their community was severely 
undermined, because their identity, spiritual traditions and way of life were founded 
upon it.57
Dignitary harm can also result from violations of trust. In the Havasupai case, 
despite promises that the blood samples would remain with the ASU researchers, the 
fact that the researchers sent samples to researchers at other institutions and that the lat-
ter researchers also published papers that stigmatised the Havasupai was disrespectful, as 
the ASU researchers violated the trust that tribe members had placed in them. 
Further, biobank sample providers and their relatives may suffer dignitary harm if 
their cell lines are immortalised, patented or commercialised without their knowledge or 
approval,58 or if samples that they invest with religious significance are tampered with, 
53 Mats G Hanson, ‘Balancing the Quality of Consent’ (1998) 24(3) Journal of Medical Ethics 182, 185; 
Buchanan (n 43) B7; Robert F Weir, ‘The Ongoing Debate About Stored Tissue Samples’ in National 
Bioethics Advisory Commission (n 43) F1, F12–F13.
54 Rebecca Tsosie, ‘Cultural Challenges to Biotechnology: Native American Genetic Resources and the 
Concept of Cultural Harm’ (2007) 35(3) Journal of Law, Medicine and Ethics 396, 403.
55 Hart and Sobraske (n 3) Witness Interview Summaries, 8; Rex Dalton, ‘When Two Tribes Go to War’ (2004) 
430(6999) Nature 500, 501.
56 Harmon (n 6).
57 Harmon (n 6); Rubin (n 9); Howard Fischer, ‘Havasupai Blood Lawsuit Reinstated’, Azdailysun (28 Novem-
ber 2008), http://azdailysun.com/news/article_2921c286–4454–57eb–926b–11e795134f8f.html; Leslie E 
Wolf, ‘Advancing Research on Stored Biological Materials: Reconciling Law, Ethics, and Practice’ (2010) 
11(1) Minnesota Journal of Law, Science and Technology 99, 126.
58 As was the case with Henrietta Lacks and John Moore. On the case of Henrietta Lacks, see Rebecca Skloot, 
The Immortal Life of Henrietta Lacks (Crown, 2010); Gail Javitt, ‘Why Not Take All of Me? Reflections on 
The Immortal Life of Henrietta Lacks and the Status of Participants in Research Using Human Specimens’ 
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lost or not returned after the research is finished. In the Havasupai case, for instance, 
the tribal belief that blood continues to retain the essence of the individual and must be 
buried after death to let the spirits rest, explains the interest of the tribe in having the 
remaining blood samples returned.59
Important Lessons from the Havasupai Case
The Havasupai case seems to offer at least three valuable lessons for current biobank 
research practices. First, researchers need to ensure that they understand and fully con-
sider the interests and concerns of their research participants. Admittedly, many research 
projects can lead to unforeseen results, meaning that the potential harms to participants 
are poorly understood before the research starts and hence may be underestimated, by 
both researchers and participants.60 Likewise, investigators tend to anticipate only the 
types of harms that they consider they themselves might experience, and are unlikely 
to recognise unique kinds of harm that their research participants might experience.61 
Culturally specific harms may seem trivial or superstitious to researchers, and hence 
not worth acknowledging.62 However, researchers have to take local cultural sensitivi-
ties seriously instead of relying only on their own judgment. After all, whether or not 
an investigator acknowledges the validity of a particular risk, it is up to the potential 
research participants to decide whether the research is justified according to their own 
values and principles. Respect for their autonomy requires that they may decide to par-
ticipate in the light of their own values and beliefs, irrespective of the point of view 
or expectations of the researcher. The advancement of scientific knowledge (and cer-
(2010) 11(2) Minnesota Journal of Law, Science and Technology 713. On the Moore case, see Karen G 
Biagi, ‘Moore v Regents of the University of California: Patients, Property Rights, and Public Policy’ (1991) 
35(2) St Louis University Law Journal 433; Helen R Bergman, ‘Case Comment: Moore v Regents of the 
University of California’ (1992) 18(1–2) American Journal of Law and Medicine 127; Russell Korobkin, ‘“No 
Compensation” or “Pro Compensation”: Moore v Regents and Default Rules for Human Tissue Donations’ 
(2007) 40(1) Journal of Health Law 1; Patricia Roche, ‘The Property/Privacy Conundrum over Human 
Tissue’ (2010) 22(3) HEC Forum 197.
 
59 Michael Kiefer, ‘Havasupai Tribe Ends Regents Lawsuit with Burial’, Arizona Republic (22 April 2010), 
www.azcentral.com/arizonarepublic/local/articles/2010/04/22/20100422arizona-havasupai-tribe-regents-
lawsuit.html. For information regarding a very similar case involving the Nuu-chah-nulth tribe of British 
Columbia, Canada, see Rex Dalton, ‘Tribe Blasts “Exploitation” of Blood Samples’ (2002) 420(6912) Nature 
111; David Wiwchar, ‘Nuu-chah-nulth Blood Returns to West Coast’, Ha-Shilth-sa (16 December 2004), 
http://caj.ca/wp-content/uploads/2010/mediamag/awards2005/%28David%20Wiwchar,%20Sept.%20
12,%202005%29Blood2.pdf.
60 Fred Beauvais, ‘Obtaining Consent and Other Ethical Issues in the Conduct of Research in American Indian 
Communities’ (1998) 14(1–2) Drugs and Society 167, 176–7; National Bioethics Advisory Commission (n 
43) 55.
61 McGregor (n 46) 362–3.
62 In the Havasupai case, principal researcher Markow stated that it had not occurred to her that the research 
might have been upsetting to the tribe members. When confronted with allegations that her research 
project had resulted in severe harm, she called these claims ‘hysterical’. See Hart and Sobraske (n 3) Witness 
Interview Summaries, 143. See also Fischer (n 57).
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tainly of academic careers) is not so important that it should trump the interests of the 
research participants.63
Secondly, the Havasupai case exposes as an illusion the standard conviction that 
ethical issues disappear when samples are anonymised. There is considerable doubt as to 
whether anonymisation can truly be achieved, since DNA has greater identifying power 
than commonly thought.64 Even if sample providers cannot be identified, though, it is 
incorrect to assume that they cannot be harmed.65 Indeed, if samples are individually 
unidentifiable, research findings can still be connected to a specific community in case 
of research involving closed groups. Moreover, even if a sample could be made totally 
anonymous, research could still result in a dignitary harm if it conflicted with the moral 
values and beliefs of the sample provider.66 As was clear from the Havasupai lawsuit, 
anonymising the samples would not have eliminated the objections of the donors.67
Finally, the example of the Havasupai shows that so much might be at stake for the 
participants that they should be allowed a right to withdraw consent and have their 
samples returned or destroyed. Only by withdrawing consent can they be enabled to 
call a halt to possible infringements on their dignity, and only by having their samples 
returned can they prevent further research that might be objectionable or—if religious 
significance is invested in the sample—restore the physical integrity of the tissue source.
V. LIMITATIONS OF FEDERAL REGULATIONS IN PREVENTING  
DIGNITARY HARMS IN BIOBANK RESEARCH
Apart from revealing that biobank research may lead to so-called dignitary harms that 
must be taken into account in evaluating research practices, the Havasupai case also 
exposes the limitations of current regulatory safeguards in preventing this kind of harm. 
More specifically, it reveals manifest flaws in the federal guidelines governing biobank 
63 McGregor (n 46) 365. Clearly, there may be exceptional cases of overwhelming public health interests 
where the interests of individuals have to come second to those of the population as a whole, such as in the 
case of a serious epidemic.
64 Zhen Lin, Art B Owen and Russ B Altman, ‘Genomic Research and Human Subject Privacy’ (2004) 
305(5681) Science 183; Dov Greenbaum, Jiang Du and Mark Gerstein, ‘Genomic Anonymity: Have We 
Already Lost It?’ (2008) 8(10) American Journal of Bioethics 71, 73; Amy L McGuire and Richard A Gibbs, 
‘No Longer De-Identified’ (2006) 312(5772) Science 370, 371; William W Lowrance and Francis S Collins, 
‘Identifiability in Genomic Research’ (2007) 317(5838) Science 600, 601; Matthias Wjst, ‘Caught You: 
Threats to Confidentiality Due to the Public Release of Large-Scale Genetic Data Sets’ (2010) 11 BMC 
Medical Ethics 21, 23.
65 National Bioethics Advisory Commission (n 43) 60–61.
66 MB Kapp, ‘Ethical and Legal Issues in Research Involving Human Subjects: Do You Want a Piece of Me?’ 
(2006) 59(4) Journal of Clinical Pathology 335, 337.
67 Henry T Greely, ‘Human Genomics Research: New Challenges for Research Ethics’ (2011) 44(2) Perspectives 
in Biology and Medicine 221, 224–5; Michelle M Mello and Leslie E Wolf, ‘The Havasupai Indian Tribe Case: 
Lessons for Research Involving Stored Biologic Samples’ (2010) 363(3) New England Journal of Medicine 
204, 206.
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research in the US, as set forth in the Code of Federal Regulations. This Code establishes 
requirements for the protection of human participants in federally funded research and 
is adopted by numerous federal agencies as a Common Rule.68 Inspired by the moral 
principles enshrined in the Nuremberg Code, the Declaration of Helsinki and the Bel-
mont Report, its provisions aim to protect the safety, welfare and dignity of human 
research participants. 
The Code of Federal Regulations requires researchers to obtain informed consent 
from research participants and approval of the research protocol by an Institutional 
Review Board (IRB)—an ethics committee set up to oversee research involving human 
participants. As a rule, potential research participants have to be provided with a written 
consent form that includes easily understandable information about the exact purpose 
of the research, the reasonably foreseeable risks and benefits, and the confidentiality pro-
cedure that will be followed.69 Before the research can go ahead, an IRB has to review 
the protocol to ascertain that adequate information will be given and that the antici-
pated benefits of the research justify its risks.70 However, federal regulations allow for 
waiver of informed consent when the IRB determines that the research involves no more 
than minimal risk to the participants, the waiver will not adversely affect the rights and 
welfare of the participants, and the research could not practicably be carried out with-
out it.71 Research is in fact completely exempt from IRB review and consequently from 
the obligation to obtain informed (re)consent if it involves only the collection or study 
of existing data or specimens which are publicly available, or where the information is 
recorded by the researcher in a way that participants cannot be identified directly or 
through identifiers linked to them.72 In its guidance from 2004 and 2008, the US Office 
for Human Research Protection (OHRP) indicated that research aiming to obtain pri-
vate information or specimens that are not individually identifiable would not trigger 
legal obligations to obtain informed consent or to seek IRB review. The OHRP specified 
that private information or specimens are to be considered not individually identifiable 
when they cannot be linked to specific individuals by the investigator directly or indi-
rectly through coding systems.73
To what extent did the Havasupai research violate these federal regulations? Apart 
from infringing basic research requirements, Markow took advantage of the fact that 
some provisions on informed consent left room for interpretation. Admittedly, the pur-
pose of the research project, as set forth in the oral script and the written consent form 
68 45 CFR § 46 (2009) (Code of Federal Regulations, Public Welfare, Protection of Human Subjects), www.
hhs.gov/ohrp/humansubjects/guidance/45cfr46.html.
69 45 CFR § 46.116(a) (2009).
70 45 CFR § 46.109 (2009) and 45 CFR § 46.111(a)(1)–(2) (2009).
71 45 CFR § 46.116(d) (2009).
72 45 CFR § 46.101(b)(4) (2009).
73 Office for Human Research Protections (OHRP), Guidance on Research Involving Coded Private Information 
or Biological Specimens (16 October 2008), www.hhs.gov/ohrp/policy/cdebiol.html.
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used during the first blood draw series, was defined broadly enough to include behav-
ioural disorders such as schizophrenia. However, contrary to Markow’s opinion,74 this 
did not mean that the Havasupai had adequately consented to the study of schizophre-
nia. After all, informed consent is not simply a signature on a form, but rather a process 
of information exchange. The scope of consent is defined on the basis of the overall 
information provided to the potential research participants.75 Since in both the discus-
sions with the tribal council and the communication with the individual participants 
only diabetes research was mentioned, the fact that the scope of the project was defined 
more broadly in the consent form was not decisive. Moreover, the meaning of the con-
sent form must be viewed from the perspective of the research participant, not from the 
viewpoint of the researcher.76 If research participants understood the vaguely formu-
lated project description to encompass only the study of diabetes, then no valid consent 
could be inferred for research that, while formally within the scope of the definition, 
went beyond this interpretation. 
Aside from the inadequate disclosure of information, doubts can be raised about 
the manner and context in which information was conveyed. More likely than not, the 
presentation of the scope of the project was not adapted to the capacities of the blood 
donors. Most of the Havasupai who were approached to give blood had no tertiary 
education, and many were barely literate in English.77 As became apparent during the 
second blood draw series, when the number of educated and motivated contributors 
diminished drastically, the information presented in the consent form proved too con-
fusing. Potential donors were very hesitant to participate and only agreed to do so after 
the research purpose was explained to them in the simplest of terms and the written 
consent form was dropped altogether.78 
The Havasupai case is not only an example of biobank research misconduct in which 
researchers disregarded the rules or bent them to their own advantage. More impor-
tantly, the wide variety of unanticipated harms that participants were confronted with 
serves as a caution that current federal regulations may be inadequate. Indeed, while 
intended to protect the interests of research participants, some of its provisions inadvert-
ently leave the door open for similar infringements.
The regulations concerning secondary research on samples which are not individu-
ally identifiable may prove especially problematic. As noted earlier, this kind of research 
is exempt from IRB review and, consequently, from the obligation to (re-)obtain 
informed consent. The rationale presumably is that no harm can be done if individual 
74 Hart and Sobraske (n 3) Witness Interview Summaries, 17, 19, 136–7.
75 Editorial, ‘Culture Clash on Consent’ (2010) 13(7) Nature Neuroscience 777. See also Tom L Beauchamp 
and John F Childress, Principles of Biomedical Ethics (Oxford University Press, 6th edn 2009) 77–97.
76 See eg Courtney S Campbell, ‘Research on Human Tissue: Religious Perspectives’ in National Bioethics 
Advisory Commission (n 43) C1, C13–C14.
77 Rubin (n 9).
78 Hart and Sobraske (n 3) Witness Interview Summaries, 31.
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participants remain anonymous. However, as was clearly demonstrated in the Havasupai 
case, major harm may befall research participants when their samples are coded but are 
known to originate within a particular population. In those circumstances, research that 
yields findings that are stigmatising and disruptive may result in severe collective harm, 
reflecting negatively on all group members. It is highly disturbing to realise that even if 
the ASU researchers had followed the regulations by the book, the population migration 
research, which proved most damaging for the participants, could have gone ahead. To 
prevent such an outcome occurring again, the National Bioethics Advisory Commission 
(NBAC) has recommended that researchers should consult with representatives of the 
relevant groups and that IRBs should not grant exemption for secondary research on 
samples which are not individually identifiable if a significant risk of group harm may 
be expected.79
A related regulatory weakness concerns the minimal risk standard that IRBs have to 
consider when balancing the risks and benefits of research that is not exempt under the 
Common Rule. If the IRB deems the risk of harm to be minimal and expects no adverse 
effects on the rights and welfare of the participants, it can allow research to proceed with-
out informed consent. While the concept is defined in the Code of Federal Regulations,80 
there is considerable confusion about what really constitutes minimal risk, leading to 
a widely varying application. As noted earlier, researchers and IRB committees tend 
to detect only the types of harms that they consider they themselves might encounter. 
Consequently, IRB review is in danger of underestimating the importance of a range of 
factors that may prove crucial for participants from a culturally distinct environment. As 
was demonstrated in the Havasupai case, several tangible and dignitary harms that are 
not generally recognisable to the research community must be factored into the ethical 
reasoning to adequately protect research participants with different values and beliefs. 
In order to obtain a satisfactory level of protection, various precautionary measures 
have been proposed. As we mentioned earlier, the NBAC has recommended consulta-
tion with representatives of relevant vulnerable groups to help evaluate the study design. 
More far-reaching proposals include continuous involvement of group representatives 
throughout the stages of study design, implementation, and dissemination of results.81 
Some commentators advocate appointing a group representative to the IRB, analogously 
79 National Bioethics Advisory Commission (n 43) vii, 73, Recommendation 17. See also Wolf (n 57) 148–9.
80 45 CFR § 46.102(i) states: ‘Minimal risk means that the probability and magnitude of harm or discomfort 
anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily 
life or during the performance of routine physical or psychological examinations or tests.’
81 eg Sally M Davis and Raymond Reid, ‘Practicing Participatory Research in American Indian Communities’ 
(1999) 69(4 Suppl) American Journal of Clinical Nutrition 577S, 757S–758S; Richard R Sharp and Morris 
W Foster, ‘Community Involvement in the Ethical Review of Genetic Research: Lessons from American 
Indian and Alaska Native Populations’ (2002) 10 Environmental Health Perspectives 145, 147; Wallwork (n 
52) 69. For the philosophical rationale behind the need for more active involvement of participants, see 
Michel Callon, Pierre Lascoumes and Yannick Barthe, Acting in an Uncertain World: An Essay on Technical 
Democracy (MIT Press, 2009).
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to the Common Rule provision on the inclusion of a prisoner representative to help 
reviewing research involving prisoners.82 The most sweeping suggestions even call for 
community informed consent to be obtained in addition to the individual informed 
consent.83 
Other, related objections can be raised against the fact that the Common Rule allows 
research participants to grant blanket consent for future, unspecified research. From 
a moral point of view, blanket consent is totally inappropriate. Respect for autonomy 
requires that research participants should know the purposes their samples will be used 
for and should have the right to authorise or reject the use in each case. To make an 
informed decision, they must have a clear picture of the harms that may befall them. 
Allowing blanket consent amounts to a lack of respect for the autonomy of participants 
because they are not provided with the information necessary to make an informed 
choice. In addition, there is a major risk of abuse if researchers may do as they please 
without considering the interests of the research participants. As the case of the Havas-
upai clearly shows, general trust in biobank researchers may be totally unwarranted. 
On the other hand, obtaining fresh informed consent for each new research use of 
human body material would be very costly and unpractical, and would significantly slow 
the pace of biobank research. An intermediate solution appears to be the only way to 
make research on stored samples feasible without compromising the dignity of partici-
pants. As recommended by the NBAC, presenting potential research participants with a 
multilayered consent form, that describes a wide range of possible uses and emphasises 
the risks and benefits of each use, could be preferable.84 In this regard, it could be noted 
that a regulatory framework seems to be developing in which the traditional empha-
sis on autonomy is superseded by a dedication to trust. More specifically, increased 
public engagement and the development of comprehensive governance structures for 
biobanks have been proposed as new mechanisms to ensure that ethical principles, 
including the dignity of biobank participants, are respected. Although the development 
of more appropriate governance structures is to be applauded, it is not inconceivable 
that consent requirements will be unduly relaxed merely because it is thought that the 
interests of research participants will be sufficiently protected by additional institutional 
82 See McGregor (n 46) 365. For the proposal to appoint a prisoner representative to the IRB, see 45 CFR § 
46.304(b) (2009) (Composition of Institutional Review Boards where prisoners are involved).
83 See Henry T Greely, ‘Informed Consent and Other Ethical Issues in Human Population Genetics’ (2001) 35 
Annual Review of Genetics 785, 789–95; C Weijer and EJ Emanuel, ‘Protecting Communities in Biomedical 
Research’ (2000) 289(5482) Science 1141, 1143.
84 National Bioethics Advisory Commission (n 43) 64, Recommendation 9. See also Timothy Caulfield, Ross 
EG Upshur and Abdallah Daar, ‘DNA Databanks and Consent: A Suggested Policy Option Involving an 
Authorization Model’ (2003) 4 BMC Medical Ethics 1, 3; Eric M Meslin and Kimberly A Quaid, ‘Ethical 
Issues in the Collection, Storage, and Research Use of Human Biological Materials’ (2004) 144(5) Journal 
of Laboratory and Clinical Medicine 229, 231; Bjørn Hofmann, Jan H Solbakk and Søren Holm, ‘Consent to 
Biobank Research: One Size Fits All?’ in Jan H Solbakk, Søren Holm and Bjørn Hofmann (eds), The Ethics 
of Research Biobanking (Springer, 2009) 3, 17–19.
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safeguards.85 One of the main challenges for the model of trust that is currently being 
elaborated is to still allow research participants maximum autonomy to determine the 
extent of their participation.
Finally, the Havasupai case also illustrates the need to regulate in more detail the 
right to withdraw consent. The Code of Federal Regulations explicitly grants that 
research participants may discontinue participation at any time without penalty or loss 
of benefit.86 However, it remains unclear what such withdrawal of consent boils down 
to in practice. Considerable disagreement exists concerning the right of participants to 
order the destruction of samples and any information gleaned from them. While it is 
frequently advocated that withdrawal should imply the destruction of all samples and 
any associated information,87 the Havasupai example reveals that this might not be 
enough.88 Where the sample itself is invested with religious significance, participants 
may have a real interest in having their samples returned instead of destroyed. It would 
not make any difference if the samples were to be made irrevocably anonymous, as is 
sometimes proposed instead of destruction. 
As the Havasupai experienced to their detriment, protections provided under the 
Common Rule, even when honoured in practice, are not always adequate to avoid 
severe infringements on the dignity of biobank research participants. Instead of merely 
encouraging researchers by way of recommendations, the federal regulations governing 
biobank research need to be updated to guarantee due consideration of dignitary inter-
ests that researchers may find difficult to identify. The safeguards built into the Common 
Rule still are too much indebted to the informed consent doctrine that was originally 
developed in the therapeutic setting. Indeed, its provisions do not yet sufficiently address 
the protection of parties other than the individuals directly participating in research 
who might be affected. In addition, by focusing almost exclusively on health, safety and 
welfare risks, they lose sight of less palpable harms that can prove to be even more prob-
lematic. 
85 For an overview of the issues at stake and various proposals for state-of-the-art governance structures, see 
Matti Häyry, Ruth Chadwick, Vilhjalmur Arnason and Gardar Arnason (eds), The Ethics and Governance 
of Human Genetic Databases: European Perspectives (Cambridge University Press, 2007); Elger et al (n 2); 
Herbert Gottweis and Alan Petersen (eds), Biobanks: Governance in Comparative Perspective (Routledge, 
2008); Kris Dierickx and Pascal Borry (eds), New Challenges for Biobanks: Ethics, Law and Governance 
(Intersentia, 2009); Kaye and Stranger (n 2); Graeme Laurie, ‘Reflexive Governance in Biobanking: On the 
Value of Policy Led Approaches and the Need to Recognize the Limits of the Law’ (2011) 130(3) Human 
Genetics 347; Herbert Gottweis and Georg Lauss, ‘Biobank Governance: Heterogeneous Modes of Ordering 
and Democratization’ (2012) 3(2) Journal of Community Genetics 61; Jane Kaye, Susan MC Gibbons, 
Catherine Heeney, Michael Parker and Andrew Smart (eds), Governing Biobanks: Understanding the 
Interplay between Law and Practice (Hart Publishing, 2012); Emmanuelle Rial-Sebbag and Anne Cambon-
Thomsen, ‘The Emergence of Biobanks in the Legal Landscape: Towards a New Model of Governance’ 
(2012) 39(1) Journal of Law and Society 113.
86 45 CFR § 46.116(a)(8) (2009).
87 eg Gert Helgesson and Linus Johnsson, ‘The Right to Withdraw Consent to Research on Biobank Samples’ 
(2005) 8(3) Medicine, Health Care and Philosophy 315, 319–20.
88 See Wolf (n 57) 155.
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In order to be better adapted to the interests of biobank research participants, the 
Common Rule needs to be revised in a number of ways. To begin with, the concept of 
harm should be broadened to account for dignitary harms to individual participants, 
third parties and groups, including possible harms resulting from research on ano-
nymised samples. Furthermore, to facilitate appropriate future use of samples, the use of 
a multilayered consent form should be required, providing potential participants with 
enough options to ascertain their preferences if the purpose of secondary research might 
differ from the purpose of primary research. Finally, the provision that participants may 
at all times discontinue participation should be made more explicit by granting a right 
to have their samples returned or destroyed. Only such a revision of existing regulations 
would ensure due protection of the interests of research participants.
VI. LIMITATIONS OF CURRENT TORT DOCTRINE IN PROVIDING RELIEF 
FROM DIGNITARY HARMS IN BIOBANK RESEARCH
The Havasupai case reveals that present common law tort doctrines are largely unhelpful 
to protect research participants when dignitary harms actually occur. Theoretically, tort 
law offers several causes of action on which biobank research participants may proceed, 
including breach of informed consent, breach of fiduciary trust, and negligent infliction 
of emotional distress.89 In practice, however, these remedies prove to be largely illusory.
Breach of Informed Consent
Courts have consistently declined to acknowledge claims for breach of informed con-
sent brought by biobank research participants against researchers. In the Havasupai case, 
for instance, the District Court for the District of Arizona dismissed this claim because 
in its opinion the consent for drawing blood was not made ineffective even if it was 
fraudulently procured.90 Even in cases where judges have opted for a less conservative 
interpretation of the informed consent doctrine, they decided that biobank research par-
ticipants did not have standing to sue for breach of informed consent. 
As with other torts based in negligence, the tort of informed consent requires a 
breach of duty, an injury and a causal connection between the duty that was breached 
and the injury. However, since this tort was imported from standard medical malpractice 
89 On the crucial importance of the liability framework to ensure effective retrospective and prospective 
accountability with regard to research injuries, see Kenneth De Ville, ‘The Role of Litigation in Human 
Research Accountability’ (2002) 9(1) Accountability in Research 17, 19; Larry I Palmer, ‘Should Liability 
Play a Role in the Social Control of Biobanks?’ (2005) 33(1) Journal of Law, Medicine and Ethics 70, 76–77.
90 Tilousi v Arizona State University Board of Regents, 2005 WL 6199562, 2 (D Ariz) (‘Plaintiffs consented to 
having blood drawn and were fully aware of the character of the contact. Thus their consent is not made 
ineffective even if defendants did make fraudulent representations to induce that consent’).
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theory, its significance outside the therapeutic setting remains unclear.91 For instance, 
courts have been very reluctant to recognise a duty of informed consent between 
biobank researchers and research participants. Admittedly, in Moore v Regents of Univer-
sity of California, the Supreme Court of California acknowledged a duty of disclosure on 
the part of a biomedical researcher, but only because he had also been the tissue donor’s 
treating physician and as such was obliged to inform his patient about any personal 
interests that might affect his medical judgment.92 In Greenberg v Miami Children’s Hos-
pital Research Institute, the District Court for the Southern District of Florida explicitly 
questioned whether biobank researchers owe participants a duty of informed consent 
in the absence of a therapeutic relationship. It argued that, even if that kind of duty 
could be established, it would surely not include disclosure of the researcher’s economic 
interests.93
Although until now no duty of informed consent has been upheld in biobank litiga-
tion, two major cases involving experimental research on human participants suggest 
that such a duty may indeed extend beyond the therapeutic context. In Whitlock v Duke 
University the District Court for the Middle District of North Carolina argued that 
because the doctrine of informed consent applies ‘in therapeutic circumstances where 
the health care provider has as an objective to benefit the patient’, informed consent 
would a fortiori be required ‘by an experimental subject in the nontherapeutic context 
where the researcher does not have as an objective to benefit the subject’.94 In deter-
mining the appropriate standard of care in such a context, the court explicitly sought 
guidance from both the Nuremberg Code and the Declaration of Helsinki, and con-
91 E Haavi Morreim, ‘Medical Research Litigation and Malpractice Tort Doctrines’ (2003) 4(1) Houston 
Journal of Health Law and Policy 1, 63.
92 In Moore v Regents of the University of California, a patient sued, among others, his treating physician 
for using cells removed from him in the course of his leukemia treatment to develop a patented cell 
line without his permission. The Supreme Court of California ruled that he had no cause of action for 
conversion but could recover for breach of fiduciary duty and lack of informed consent, holding that ‘(1) a 
physician must disclose personal interests unrelated to the patient’s health, whether research or economic, 
that may affect the physician’s professional judgment; and (2) a physician’s failure to disclose such interests 
may give rise to a cause of action for performing medical procedures without informed consent or breach 
of fiduciary duty’. See Moore (n 1) 483.
93 In Greenberg v Miami Children’s Hospital Research Institute, Inc, 264 F Supp 2d 1064, 1070 (SD Fl 2003), 
parents of children who donated tissue and blood samples for Canavan disease research filed suit against 
the research institute for developing a patented screening test without their permission. The District Court 
for the Southern District of Florida dismissed the plaintiffs’ claim for lack of informed consent. It declined 
‘to extend the duty of informed consent to cover economic interests’ and rejected the plaintiffs’ invocation 
of the Moore ruling, stating that ‘[t]he allegations in the Complaint are clearly distinguishable as [the] 
Defendants here are solely medical researchers and there was no therapeutic relationship as in Moore’.
94 Whitlock v Duke University, 637 F Supp 1463, 1468 (MD NC 1986). In this case, a research participant who 
sustained severe organic brain damage during a deep-diving simulation sued the research institution for 
failing to obtain adequate informed consent because it had failed to warn about the risk of organic brain 
damage. Although the court acknowledged a ‘higher level of risk disclosure applicable to nontherapeutic 
experimentation’, it ultimately dismissed the claim because ‘no genuine issue of fact exists as to whether the 
risk of organic brain damage unique to experimental deep diving was a reasonably foreseeable risk’ (1472).
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cluded that informed consent in the nontherapeutic context would have to be consistent 
with the Code of Federal Regulations.95 Similarly, in Grimes v Kennedy Krieger Insti-
tute the Maryland Court of Appeals found that researchers involved in nontherapeutic 
human experimentation face a duty under certain circumstances to obtain informed 
consent from the participants.96 As in Whitlock, the court acknowledged the authority 
of the Nuremberg Code and the Declaration of Helsinki and affirmed that the Code of 
Federal Regulations established the appropriate standard of care.97
However, even if the duty of informed consent is judicially enforced in the distinct 
context of biobank research, plaintiffs may not succeed in their claim because their inju-
ries are not cognisable under malpractice law. Because biobank research participants will 
fail to prove that they suffered a visible physical injury or recognisable psychiatric illness 
as a direct consequence of the breach of duty, their claim for breach of informed con-
sent will be dismissed. Anticipating this, biobank research participants have attempted 
to bring an additional cause of action directly under the Code of Federal Regulations. 
They have asserted that they are third-party beneficiaries to the contract between the 
research institution and the Department of Health and Human Services in which the 
researchers agree to abide by the Common Rule. However, as happened in the Havasupai 
case,98 courts have systematically declined to extend a private right of action to enforce 
the terms of the Code of Federal Regulations.99 Acknowledging that these regulations 
require protective measures on the part of investigators and research institutions, courts 
95 Ibid, 1471.
96 In Grimes v Kennedy Krieger Institute, Inc 782 A 2d 807, 858 (Md 2001), research subjects participating in a 
study testing lead abatement techniques filed suit against the research institution that sponsored the study 
for failing to inform them about dangerous lead levels in their blood as well as for lack of informed consent. 
The Maryland Court of Appeals held that ‘under certain circumstances, [informed consent agreements in 
nontherapeutic research projects] can, as a matter of law, constitute “special relationships” giving rise to 
duties, out of the breach of which negligence actions may arise’. The appellate court held that the trial court 
had erred in granting the research institution’s motions for summary judgment and remanded the case for 
further proceedings consistent with its opinion.
97 Ibid, 848–51, 858.
98 The District Court for the District of Arizona dismissed the plaintiffs’ cause of action for violation of 45 
CFR § 46.116, ruling that ‘this federal regulation regarding institutional review boards does not provide a 
private right of action nor does it evidence an intent to do so. A court must determine whether a statute 
“displays an intent to create not just a private right but also a private remedy” … The text and structure of 
the statute display no intent to establish a private right of action.’ Tilousi (n 90) 2.
99 In Wright v Fred Hutchinson Cancer Research Center, 269 F Supp 2d 1286, 1289 (WD Wash 2002), the 
plaintiffs, representing 20 deceased cancer patients who had participated in a trial to prevent graft failure 
in bone marrow transplantation, sued the research institution for alleged use of misleading consent forms 
and failure to disclose conflicts of interest. The plaintiffs claimed that as a result the research institution 
failed to abide by the Code of Federal Regulations and breached its contract with the Department of Health 
and Human Services. The District Court for the Western District of Washington dismissed the plaintiffs’ 
cause of action under the Code of Federal Regulations on the grounds that ‘agency regulations cannot give 
rise to a private cause of action where the authorizing statute does not confer such a right’ and ‘[b]ecause 
plaintiffs have not identified any statutory basis for the private rights of action they seek to assert, their 
claims … must fail.’ See also Washington University v Catalona, 437 F Supp 2d 985, 1000 (ED Mo 2006).
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have insisted that violations only allow the funding agency to impose penalties or even 
withdraw federal funds; they do not mandate enforcement through private litigation.100 
Indeed, parties that benefit from a government contract are assumed to be no more 
than incidental beneficiaries unless the contract explicitly focuses on them and provides 
them with an actionable right.101 Since this intent is clearly absent in the Code of Fed-
eral Regulations, courts have denied biobank research participants a basis for a judicial 
remedy where researchers disregard the regulatory requirements for informed consent.
Breach of Fiduciary Duty
A cause of action for breach of fiduciary duty proves to be similarly ineffective in pro-
tecting biobank research participants. As was the case in the Havasupai lawsuit, biobank 
research participants have argued that they put special trust in their researchers and 
even perceive them as fiduciaries.102 In their view, biobank researchers must be held to 
the highest standard of care, put the interests of their research participants before their 
personal interests, and at least protect them from unreasonable harm. 
However, courts have emphasised that biobank researchers are not fiduciaries of 
their research participants for largely the same reasons that they have dismissed a duty of 
informed consent on their part. They have found the fiduciary doctrine to be applicable 
only in the strictly medical context, where a physician is acting primarily for the benefit 
of the patient. By contrast, in biobank research, which is typically not undertaken for the 
benefit of individual participants, no fiduciary duties are said to apply, except, as under-
scored in the Moore case, for researchers who have a close physician-patient relationship 
with their research participants.103 The suggestion in Whitlock and Grimes, that in the 
context of experimental research on human beings a heightened duty may exist even 
outside the strict physician-patient relationship,104 has not been followed in biobank 
research litigation. For instance, the Greenberg court clearly stated that no automatic 
fiduciary relationship attaches when biobank researchers accept tissue donations; such 
a relationship will only be established when researchers explicitly accept the trust placed 
in them.105
100 Wright (n 99) 1289–90.
101 John Calamari and Joseph Perillo, The Law of Contracts (West, 4th edn 1998) 643.
102 Tilousi (n 90) 2.
103 Moore (n 1) 485 (‘Accordingly, we hold that a physician who is seeking a patient’s consent for a medical 
procedure must, in order to satisfy his fiduciary duty … disclose personal interests unrelated to the patient’s 
health, whether research or economic, that may affect his medical judgment’).
104 Whitlock (n 94) 1468; Grimes (n 96) 858. See ibid, 835 (‘We shall hold initially that the very nature of 
nontherapeutic scientific research on human subjects can, and normally will, create special relationships 
out of which duties arise’); ibid, 849 (‘The question becomes whether this duty of informed consent 
created by federal regulation, as a matter of state law, translates into a duty of care arising out of the 
unique relationship that is researcher-subject, as opposed to doctor-patient. We answer that question in the 
affirmative’).
105 Greenberg (n 93) 1071–2 (‘[A] fiduciary relationship will only be found when the plaintiff separately 
alleges that the plaintiff placed trust in the defendant and the defendant accepted that trust … [T]he Court 
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Because the element of acceptance of trust cannot be sufficiently alleged in biobank 
research litigation, claims for breach of fiduciary duty have consistently been dis-
missed.106 Moreover, even if a fiduciary responsibility on the part of biobank researchers 
were automatically allocated, disgruntled research participants would find it very dif-
ficult to recover under a claim for breach of fiduciary duty. Since this cause of action 
sounds in negligence, plaintiffs would have to prove that they suffered physical injury or 
provable psychiatric injury as a direct consequence of the researchers’ breach of duty. As 
dignitary harms are not by themselves considered to be compensable injuries under this 
tort, biobank research participants would most likely be left out in the cold.107
Negligent Infliction of Emotional Distress
With both the tort of breach of informed consent and breach of fiduciary duty inad-
equate to protect the autonomy and dignity of biobank research participants, a claim 
for negligent infliction of emotional distress may offer them some, albeit slim, hope for 
recovery. Because this cause of action does not rely on medical malpractice doctrine, 
the applicable standard of care that researchers must live up to is not restricted to the 
confines of the physician-patient setting. Moreover, injuries that are not ordinarily rec-
ognised in medical malpractice litigation are more likely to be acknowledged.
However, while there is indeed a tendency to recognise a broader category of harms, 
courts still refuse to compensate for emotional suffering unless this has resulted in last-
ing physical symptoms or a provable psychiatric injury. For instance, in the Havasupai 
case, the District Court denied the defendants’ motion to dismiss the negligent infliction 
of emotional distress claim because the plaintiffs’ complaint alleging severe emotional 
harm might have been adequate if they could present evidence of a long, continuous 
mental disturbance that might be classified as illness.108
We have to conclude that all three causes of action under consideration leave biobank 
research participants largely unprotected and, consequently, they appear too limited to 
finds that Plaintiffs have not sufficiently alleged the second element of acceptance of trust by Defendants 
and therefore have failed to state a claim. There is no automatic fiduciary relationship that attaches when 
a researcher accepts medical donations and the acceptance of trust, the second constitutive element of 
finding a fiduciary duty, cannot be assumed once a donation is given’).
 
106 For instance in the case under consideration. See Tilousi (n 90) 2 (‘plaintiffs allege no facts sufficient to 
establish [a fiduciary relationship]. As defendants point out, plaintiffs do not even allege that any of the 
defendants accepted the trust and confidence of plaintiffs, but instead plaintiffs’ allegations focus on Martin 
and Benyshek’s perception that the Havasupai trusted Martin … This does not establish that defendants 
accepted the trust of plaintiffs’).
107 Donna M Gitter, ‘Ownership of Human Tissue: A Proposal for Federal Recognition of Human Research 
Participants’ Property Rights in their Biological Material’ (2004) 61 Washington & Lee Law Review 257, 307; 
Ellen W Clayton, ‘Informed Consent and Biobanks’ (2005) 33(1) Journal of Law, Medicine and Ethics 15, 18.
108 Tilousi (n 90) 4 (‘Plaintiffs’ complaint alleging continued mental and emotional harm may be adequate for 
a claim of bodily harm if plaintiffs can present evidence to establish long continued mental disturbance 
of the sort contemplated by the Restatement. Therefore, the motion to dismiss the negligent infliction of 
emotional distress claim … is denied’).
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be of any real significance in the specific biobank research context. In order to establish 
the elements of negligence necessary to sustain their tort claims, research participants 
would have to prove that the researcher owed them a duty of special care, that this duty 
was breached, that they suffered a cognisable injury, and that the researcher’s breach of 
duty was the proximate cause of their injury. The burden on biobank research partici-
pants to prove all four elements may be practically insurmountable.109 Even if courts 
were to acknowledge that biobank researchers owe their participants a duty of special 
care and are found to be in breach of this duty, plaintiffs would have a very hard time 
demonstrating that they suffered an injury that not only qualifies under present tort 
doctrine but had unquestionably been caused by the negligent conduct of the defend-
ants.
VII. AVENUES FOR MODIFYING TORT DOCTRINE TO PROTECT  
BIOBANK RESEARCH PARTICIPANTS
It seems that existing tort law must be substantially revised to address the kinds of mis-
treatment that are specific to the biobank research context and which result in injuries 
that affect the autonomy and dignity of participants without demonstrable physical 
damage. Two potential avenues can be identified to achieve this goal. The first approach 
involves an expansion of existing remedies, while the second focuses on the development 
of a distinct dignitary tort.
Expanding Existing Remedies
In an attempt to offer biobank research participants an opportunity to recover for 
infringements on their autonomy and dignity, a three-pronged proposition to modify 
existing tort remedies may be considered. First of all, tort law should recognise a fiduci-
ary relationship between researchers and the persons on whose body material they carry 
out research.110 This would go beyond the existing position, where such a relationship is 
only acknowledged in the context of therapeutic research, as well as beyond the rulings 
in Whitlock and Grimes, which related to specific non-therapeutic research contexts but 
not to that of biobank research.
109 MaryJoy Ballantyne, ‘One Man’s Trash is Another Man’s Treasure: Increasing Patient Autonomy through 
a Limited Self-Intellectual Property Right’ (2005) 3 Georgetown Journal of Law and Public Policy 567, 578; 
Natalie Ram, ‘Assigning Rights and Protecting Interests: Constructing Ethical and Efficient Legal Rights in 
Human Tissue Research’ (2009) 23(1) Harvard Journal of Law and Technology 119, 157.
110 See eg Lori B Andrews, ‘Harnessing the Benefits of Biobanks’ (2005) 33(1) Journal of Law, Medicine and 
Ethics 22, 27; Ram (n 109) 173. Biobank research participants could even be allowed a cause of action 
directly under the Code of Federal Regulations, if federal legislation were to rephrase the regulatory 
requirements in terms of the persons benefited and establish clear and uniform rules of engagement 
between all parties concerned. See Javitt (n 58) 754.
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Secondly, because a cause of action for breach of fiduciary duty would still fail for 
want of cognisable injury, the scope of harm actionable under the negligence doctrine 
must be expanded to include dignitary harms that may result from biobank research 
misconduct. Although in cases of biobank research litigation, courts have systematically 
refused to impose liability for these kinds of harms, they have allowed recovery for types 
of harms that are of a non-physical nature in other litigation contexts, for instance in 
cases involving breach of privacy or defamation. There is no reason why negligence torts 
could not be similarly conceived.111 A key argument in favour of this proposal, as was 
suggested decades ago, is that the prime interests protected by negligence torts ought to 
be the individual’s autonomy and dignity instead of their interest in being free of physi-
cal injury caused by negligent action.112
A claim for recovery for dignitary harm has already been considered in Diaz v 
Hillsborough County Hospital Authority, a case involving inadequately consented-to clin-
ical research. The plaintiffs in this case claimed that, even though they had not suffered 
any physical injuries, they had been harmed by conduct that ‘overrode their autonomy, 
treated them as less than human, and denigrated them as human beings’.113 When the 
court refused to dismiss the case and certified the case as a class action, a multi-million 
dollar settlement was reached that was judicially approved on the basis of a right to 
111 E Haavi Morreim, ‘Litigation in Clinical Research: Malpractice Doctrines versus Research Realities’ (2004) 
32(3) Journal of Law, Medicine and Ethics 474, 479–80; Ram (n 109) 158–9.
112 eg Joseph Goldstein, ‘For Harold Lasswell: Some Reflections on Human Dignity, Entrapment, Informed 
Consent, and the Plea Bargain’ (1975) 84 Yale Law Journal 683, 691; Jay Katz, ‘Informed Consent: A Fairy 
Tale? Law’s Vision’ (1977) 39(2) University of Pittsburgh Law Review 137, 161; Marjorie M Shultz, ‘From 
Informed Consent to Patient Choice: A New Protected Interest’ (1985) 95(2) Yale Law Journal 219, 276; 
Alan Meisel, ‘A “Dignitary Tort” as a Bridge Between the Idea of Informed Consent and the Law of Informed 
Consent’ (1988) 16(3–4) Law, Medicine and Health Care 210, 210–11; Aaron D Twerski and Neil B Cohen, 
‘Informed Decision Making and the Law of Torts: The Myth of Justiciable Causation’ (1988) 3 University 
of Illinois Law Review 607, 621–2. In the meantime, the right to recover for dignitary harm in the absence 
of physical damage or pecuniary loss has already been acknowledged in medical malpractice litigation. See 
eg Lugenbuhl v Dowling, 701 So 2d 447, 455–6 (LA Supreme Court 1997) (‘While plaintiff failed to prove 
physical damages or pecuniary loss, he is still entitled to an award of general compensatory damages caused 
by the doctor’s breach of duty. In this type of case, damages for deprivation of self-determination, insult 
to personal integrity, invasion of privacy, anxiety, worry and mental distress are actual and compensatory 
… Rather, the injury was to plaintiff ’s personal dignity and right of privacy, an injury for which an award 
of damages generally is considered appropriate. The primary concern in this injury to the personality is 
vindication of valuable, although intangible, right, the mere invasion of which constitutes harm for which 
damages are recoverable’).
113 In Diaz v Hillsborough County Hospital Authority, 2000 WL 1682918, 3 (MD Fla), a group of about 5,000 
women brought a class action suit against the hospital that subjected them to research into a new method 
for fetal lung maturity treatment during their prenatal care. The plaintiffs claimed that, although they 
had signed the informed consent document informing them that they would be subjected to a treatment 
method that did not satisfy the regular standard of care, their consent was invalid because it was obtained 
in a coercive atmosphere and because the forms were written in language that they could not possibly 
understand. They asserted that their interest in refusing unwanted research had been violated as a result. 
See Stephen F Hanlon and Robyn S Shapiro, ‘Ethical Issues in Biomedical Research: Diaz v Hillsborough 
County Hospital Authority’ (2003) 30(2) Human Rights 16, 17.
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recover for dignitary harm.114 Although the court’s consent decree lacks the precedent-
setting force of a court ruling, the case is notable as the first litigation to have produced 
a substantial monetary award to biomedical research participants who did not assert a 
claim of physical injury.115
Thirdly and relatedly, the negligence doctrine could be modified to ease the burden 
of proof on biobank research participants to demonstrate that they suffered dignitary 
harm, because the difficulties in proving this kind of harm would otherwise likely be 
insurmountable.
Introducing a New Dignitary Tort
A second avenue for improving protection of the autonomy and dignity of biobank 
research participants would be for the courts to accept a distinct dignitary tort.116 The 
need for an explicit recognition of a genomic tort claim based on an interest in dignity 
has been forcefully advocated by several commentators.117 Relying on a conception of 
human dignity as essentially empowering,118 they persuasively argue that persons should 
have the ability to control the flow of genetic information about themselves. Such a claim 
of the right to control personal genetic information could emerge either as part of a broad 
concept of privacy or as emanating from a proprietary interest that individuals might 
114 Diaz, ibid, 3; Ana Iltis, ‘Lay Concepts in Informed Consent to Biomedical Research: The Capacity to 
Understand and Appreciate Risk’ (2006) 20(4) Bioethics 180, 183 fn 17; Morreim (n 91) 78–79.
115 Carl H Coleman, ‘Duties to Subjects in Clinical Research’ (2005) 58(2) Vanderbilt Law Review 387, 447; 
Hanlon and Shapiro (n 113).
116 Apart from initiating new types of claims, research participants now tend to sue not only the primary 
researcher and others directly involved in the research project, but also academic institutions and even 
individual members of the IRBs. For an in-depth analysis of the recent evolution of research litigation, see 
Michelle M Mello, David M Studdert and Troyen A Brennan, ‘The Rise of Litigation in Human Subjects 
Research’ (2003) 139(1) Annals of Internal Medicine 40, 42; David B Resnik, ‘Liability for Institutional 
Review Boards: From Regulation to Litigation’ (2004) 25(2) Journal of Legal Medicine 131, 135; Randi 
Z Shaul, Shelley Birenbaum and Megan Evans, ‘Legal Liabilities in Research: Early Lessons from North 
America’ (2005) 6(4) BMC Medical Ethics 1, 1–2.
117 See Graeme Laurie, Genetic Privacy: A Challenge to Medico-Legal Norms (Cambridge University Press, 
2002); Roger Brownsword, ‘An Interest in Human Dignity as the Basis for Genomic Torts’ (2003) 42(3) 
Washburn Law Journal 413.
118 Brownsword and others have made it clear that, with the advent of the technological era, the concept of 
‘human dignity as empowerment’ has been supplemented by the concept of ‘human dignity as constraint’. 
The argument in favour of recognising a dignitary genomic tort is founded on the former, in that it is 
based on respect for the autonomy of persons. For the distinction between these conceptions of human 
dignity, see eg Deryck Beyleveld and Roger Brownsword, Human Dignity in Bioethics and Biolaw (Oxford 
University Press, 2001); Daniela-Ecaterina Cutas, ‘Looking for the Meaning of Dignity in the Bioethics 
Convention and the Cloning Protocol’ (2005) 13(4) Health Care Analysis 303; Roger Brownsword, ‘Genetic 
Engineering, Free Trade and Human Rights: Global Standards and Local Ethics’ in Daniel Wüger and 
Thomas Cottier (eds), Genetic Engineering and the World Trade System (Cambridge University Press, 
2008) 287; Roger Brownsword, ‘Human Dignity, Biolaw, and the Basis of Moral Community’ (2010) 21(4) 
Journal International de Bioethique 21.
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have in their genetic information.119 Taking into consideration that accepting proprie-
tary rights in relation to genetic information is likely to entail recognition of proprietary 
rights to the very tissue or samples that hold genetic information—an assumption that 
is deeply contested—a non-property approach focusing on the right to privacy may be 
most promising. In either case, a genomic tort claim based on an interest in dignity 
would give a cause of action both when genetic information has been obtained and 
passed on without the authorisation of the subject of the information and when genetic 
information has been obtained about which the subject of the information may wish to 
remain ignorant.120 Such a general dignitary tort could even serve as the backbone for 
the development of more specific genomic torts, such as a tort relating to the violation of 
the right to prohibit or restrict access, or a tort relating to the violation of the right not to 
know.121 Covering at the same time unauthorised outward transmission and unwanted 
inward transmission of genetic information, this approach would offer a judicial remedy 
for all injustices suffered by the Havasupai tribe. 
A similar way to circumvent the difficulties of recovering for non-physical harms 
under present tort doctrine could be the introduction of a dignitary cause of action 
based directly on international ethics codes. Recently, plaintiffs in several cases involving 
clinical research and human experimentation have adopted this tactic by filing a separate 
action for breach of the ‘right to be treated with dignity’.122 For instance, in Robertson v 
McGee and Wright v Fred Hutchinson Cancer Research Center, the plaintiffs claimed that 
the Nuremberg Code and the Declaration of Helsinki, which set the minimum accept-
able standards for conducting research on human participants, are essentially world 
statutes that create a ‘right of every human subject to be treated with dignity’ on the 
part of all citizens of the United States.123 Anticipating that the court would deny them 
a private right of action under these international research ethics codes, the plaintiffs 
asserted that these documents are evidence that the United States recognises that certain 
rights are fundamental under the due process clause of the Fourteenth Amendment and 
that violation of these rights will give rise to liability under § 1983 of the Civil Rights Act. 
119 Laurie (n 117) 84, 225–6; Brownsword (n 117) 444, 462.
120 Brownsword (n 117) 417.
121 Ibid, 486.
122 Mello, Studdert and Brennan (n 116) 41; Richard S Saver, ‘Medical Research and Intangible Harm’ (2006) 
74 University of Cincinnati Law Review 941, 974–6.
123 In Robertson v McGee, 2002 WL 535045, 2–3 (ND Okla 2002), research participants and representatives 
of deceased research participants in a melanoma vaccine trial filed a lawsuit against, among others, the 
principal investigator and the hospital. Just as in Wright v Fred Hutchinson Cancer Research Center, the claim 
for lack of informed consent, alleging failure to disclose all relevant risks during the consent procedure, was 
supported by a separate claim for breach of the right to be treated with dignity. The case was eventually 
dismissed for lack of jurisdiction. See www.sskrplaw.com/files/robertson_complaint.pdf. See also Wright 
(n 99) 1288, www.sskrplaw.com/files/wright_complaint.pdf. Similar actions for breach of the right to be 
treated with dignity were filed in Berman v Fred Hutchinson Cancer Research Center; Aderman v Trustees 
of the University of Pennsylvania; Beth Wade v Oregon Health and Science University; Guckin v Nagle and 
Steubin v Kornak: see www.sskrplaw.com/lawyer-attorney-1472350.html.
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However, in both cases the court rejected the plaintiffs’ due process claim because 
the defendants’ alleged actions in failing to obtain informed consent were in direct 
contravention of state procedures that were themselves in accord with the protections 
guaranteed by the Constitution and because tort law provided adequate post-depriva-
tion remedies for the defendants’ alleged conduct.124 
Indeed, until now the courts have not been receptive to allowing a dignitary cause 
of action based on the Nuremberg Code or Declaration of Helsinki. As indicated by 
Whitlock and Grimes, these international ethics codes are at most considered useful 
instruments in defining the standard of care that researchers have to observe under a 
standard negligence theory of liability.125
If a ‘right to be treated with dignity’—whether as part of a broad concept of privacy 
or based on international ethics codes—were to be recognised, research participants 
who have not been physically harmed would have a distinct dignitary tort with which 
to sue researchers, without having to establish the elements of negligence.126 To begin 
with, it would no longer be necessary to demonstrate that the researchers were subject to 
a fiduciary duty that had been breached. Moreover, biobank research participants would 
no longer have to prove that they suffered a cognisable injury. Since a breach of the ‘right 
to be treated with dignity’ would automatically result in compensable injury, an explicit 
judicial recognition that infringing on the dignity of biobank research participants con-
stitutes damage in itself, would no longer be necessary.
However, creating a ‘dignitary tort’ would also appear to have significant drawbacks. 
If a ‘dignitary tort’ were to be recognised by the courts, it would inevitably extend beyond 
the sphere of research on human body material. Therefore it would be difficult to pre-
vent it from interfering with ordinary human interactions.
To ensure that the likelihood of dignitary harms occurring in the context of research 
on human subjects is reduced or avoided, it would seem necessary to follow the first 
avenue we identified, involving creating appropriate statute law and amending the Code 
of Federal Regulations, as argued above.
In order to provide research participants with access to appropriate redress when 
dignitary harm does occur, existing tort remedies should be modified. First, a fiduciary 
relationship between researchers and the persons on whose body material they carry out 
research should be recognised. Second, dignitary harms should be acknowledged to be 
actionable harms.127 Third, since dignitary harm may not result in physical injury or 
124 Robertson (n 123) 3–4; Wright (n 99) 1294.
125 Whitlock (n 94) 1470–1; Grimes (n 96) 834. See also In re Cincinnati Radiation Litigation, 874 E Supp 796, 
821–2 (SD Ohio 1995); White v Paulsen, 997 F Supp 1380, 1383–4 (ED Wash 1998); Heinrich v Sweet, 62 F 
Supp 2d 282, 321 (D Mass 1999).
126 De Ville (n 89) 23; Resnik (n 116) 159.
127 In this regard, the opinion voiced by the appellate court in the Havasupai case seems to offer a signpost. 
By way of obiter dictum, the judges considered that dignitary torts such as those alleged by the Havasupai 
tribe do not require proof of physical manifestation of emotional suffering or distress, because these torts 
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emotional distress, the required burden of proof as to the existence, but not necessarily 
the extent, of dignitary harm, should be low.128
VIII. CONCLUSION
With human tissue research entering the era of large-scale genomic biobanking, new 
ethical and legal challenges arise in reconciling societal interests relating to the produc-
tion of scientific knowledge with the interests and concerns of research participants. As 
the Havasupai case painfully illustrates, this delicate act of reconciling different sorts of 
interests and concerns should not be restricted to the safety, ownership and confiden-
tiality considerations that dominate much of the present discussions. Indeed, especially 
but not exclusively in research on vulnerable populations, important so-called dignitary 
interests may also come into play. The Havasupai case holds particularly valuable lessons 
regarding appropriate consent requirements, the level of protection offered by anonymi-
sation procedures, and the scope of participants’ right to withdraw consent. 
The challenges arising from the emerging field of biobank research are in urgent 
need of more adequate consideration. In order to reduce the likelihood of research par-
ticipants suffering dignitary harm, the Code of Federal Regulations needs to be revised 
along the lines suggested above. This on its own, however, will not allow research par-
ticipants to obtain redress in relation to any harm they suffer. Therefore, other steps are 
necessary. Since we believe the creation of a distinct new ‘dignitary tort’ to be fraught 
with problems, we recommend instead an expansion of the availability and extent of 
existing tort remedies. First, a fiduciary relationship between researchers and the persons 
on whose body material they carry out research should be recognised. Second, dignitary 
harms should be acknowledged to be actionable harms. Third, the required burden of 
proof as to the existence of dignitary harms should be low.
have to be considered damage in themselves. As regards dignitary torts, the Court of Appeals emphasised 
that injury need not be established because it is presumed. See Havasupai Tribe (n 31) 1081. The majority 
explicitly referred to the fact that, in dignitary torts such as invasion of privacy, cognisable injury is 
presumed. In addition, they referred to Dan Dobbs’s contention that a dignitary tort is said to be damage 
in itself. Expanding on the concept of dignitary torts, Dobbs writes that ‘a violation of a dignitary right is 
harm in itself. Here the idea does not seem to be that the plaintiff really has pecuniary loss and that the only 
problem is proving it. Nor does it seem to be that the plaintiff has actual substantial emotional harm that is 
unproven. Rather the idea seems to be that some rights are “valuable” in an important although intangible 
way, even if their loss does not lead to either pecuniary loss or compensable emotional harm. The invasion 
of such a right is harm for which damages are recoverable.’ Dobbs (n 52) 625. Since the case was eventually 
settled, it remains unclear whether these considerations would have been legally decisive if the case had 
been fully litigated.
 
128 Lowering the burden of proof as to the existence of dignitary harm(s) would make it easier for the 
complainant to be heard in full trial. Clearly, the size of any award made by the court would have to be 
based upon the extent and severity of the dignitary harm(s) as established by testimony.
